Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.